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Abstract 
Structural Homology of Alpha and Beta Subunits 
of the GABAa/Benzodiazepine Receptor as Demonstrated 
by Monoclonal Antibodies and Limited Proteolysis 
Robert Thomas Malison 
1987 
Molecular aspects of GABAa/benzodiazepine receptor structure, 
including putative receptor heterogeneity, were studied. Using 
affinity chromatographic techniques, a partially purified 
benzodiazepine receptor preparation was obtained from rat brain. A 
major protein band of 48.5 kD and several minor bands (68, 58, 54.5, 
and 50 kD) were isolated. Electrophoretic analysis in one and two 
dimensions demonstrates co-localization of this 48.5 kD protein with 
the photo-labeled alpha subunit. Using this benzodiazepine receptor 
preparation, 6 murine monoclonal cell lines were generated, as tested 
for by solid phase radioimmunoassay. Western blots to receptor 
proteins separated electrophoretically demonstrate the presence of 
two immunoreactive bands of 48.5 and 54.5 kD, corresponding to the 
alpha and beta subunits. Specificity of one monoclonal antibody, E9, 
for the alpha subunit (48.5 kD) was confirmed by two dimensional 
gel electrophoresis. Immunoblot studies using another monoclonal 
antibody, H10, suggest a common epitope is shared by both 
subunits. The molecular basis underlying subunit relatedness was 
explored by limited protelytic degradation of the iodinated 
iii 

benzodiazepine receptor preparation. Results indicate that 
degradation of both 48.5 kD and 54.5 kD proteins yielded several 
shared limiting peptides as determined by molecular weight. 
Homology of these receptors may, thus, exist at the level of primary 
protein structure. 
iv 
•*!X 
1 
Introduction 
Gamma-aminobutyric acid (GABA), an inhibitory 
neurotransmitter, is widely distributed in the mammalian central 
nervous system. Concentrations in the human brain, though 
regionally variable, are measured in pmoles/gram, three orders of 
magnitude greater than concentrations typical of the monoamines 
(Fahn and Cote, 1968). Estimates suggest that GABA may be a 
neurotransmitter at 30% of synapses in the brain. The primary 
action of GABA is inhibitory, resulting in an increased chloride flux 
across and subsequent hyperpolarization of neuronal cell membranes 
(Krnjevic,1974; Curtis & Johnston,1974). With recognition of its role 
as one of the brain's major inhibitory transmitters, substantial efforts 
have been made to implicate GABA in the pathophysiology of 
numerous neurologic and psychiatric disorders, including epilepsy 
(Olsen et al, 1985), Huntington's disease (Van Ness et al, 1982), 
affective disorders (Emrich et al, 1980), and anxiety (Tallman et al, 
1980). 
Various lines of investigation have shown that a host of 
compounds, including the 1,4-benzodiazepines, are capable of 
modifying post-synaptic responses to GABA. Specifically, 
electrophysiologic studies demonstrated enhanced GABA-ergic 
transmission in the presence of benzodiazepines (Schmidt et al, 1967; 
review by Tallman et al 1980 & Haefley et al, 1981). Investigations 
into the molecular basis for the benzodiazepine's effect resulted in 
the demonstration of a high-affinity binding site (receptor) in the 
CNS (Squires & Braestrup, 1977; Mohler & Okada, 1977). Binding 
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studies in vitro fulfill criteria for a pharmacologic receptor; namely, 
binding is rapid, reversible, stereospecific and saturable. In addition, 
the rank order potency of benzodiazpines’ ability to displace 
diazepam from this central site correlates significantly with both 
activity in animal behavioral tests predictive of benzodiazepine 
potency (Braestrup & Squires, 1978; Mohler & Okada, 1978) and 
therapeutic doses in humans (Tallman et al, 1980). 
This high affinity central receptor has been shown to be 
functionally linked to the chloride channel-linked GABA receptor, 
known as the GABAa receptor (a second, G-protein-linked GABAb 
receptor has been described by Bowery & Hill, 1980, and is not 
associated with benzodiazepine binding). Binding of GABA and 
related agonists to a low affinity (1-5 pM) site on this GABAa 
receptor complex facilitates the binding of benzodiazepines (Tallman 
et al, 1978). This binding is blocked by the GABA antagonist 
(+)bicuculline. Thus, the central binding sites for both GABA and the 
benzodiazepines appear to be allosterically linked and most likely 
reside within the same protein complex. 
As research into the molecular nature of the GABAa 
/benzodiazepine receptor complex has progressed, the existence of 
benzodiazepine receptor subtypes in different brain regions has been 
hypothesized (Seighart & Karobath, 1980). Initial evidence 
supporting this hypothesis came from binding studies using the 
triazolopyridazine, CL218,872, a compound shown to interact at the 
benzodiazepine receptor. Results were consistent with receptor 
heterogeneity or negative cooperativity in a number of brain regions, 
most notably the hippocampus (Squires et al, 1979; Klepner et al, 
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1979). Autoradiographic localization at the light microscopic level 
supported a heterogeneity of receptors, as well (Young & Kuhar, 
1980; Young et al, 1981; Niehoff et al, 1982). 
In addition to pharmacologic and autoradiographic lines of 
evidence, photo-labeling studies with several photo-activated 
compounds have pointed to a structural heterogeneity of receptor 
subtypes at the molecular level. Early alkylating compounds, 
irazepine (Rice et al, 1979) and kenazepine (Williams et al, 1980), 
were able to distinguished between apparently different receptor 
subtypes (Skolnick et al, 1982). Introduction of the nitro-containing 
benzodiazepine, [3H]-flunitrazepam, not only enabled the 
autoradiographic localization studies mentioned above, but also 
allowed electrophoretic analysis of the molecular structure of the 
benzodiazepine receptor under denaturing conditions. Such photo¬ 
labeling experiments have demonstrated the existence of a major 
band, the alpha subunit, in rat brain with a molecular weight of 
approximately 50 kD (Mohler et al, 1980; Thomas & Tallman, 1981). 
A second protein band on acrylamide gels, the beta subunit, 
demonstrates a molecular weight of approximately 55 kD. It appears 
to exist in hippocampus and striatum (Sieghart & Karobath, 1980; 
Sieghart et al, 1983), as well as being expressed early in postnatal 
development (Eichinger & Sieghart, 1986). Additional minor bands 
of 53 kD and 59 kD have also been described (Sieghart et al, 1983). 
The relationship of these various proteins to the GABAa 
/benzodiazepine receptor complex and to one another remains to be 
defined. 
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With improved affinity chromatography and specific ligand 
elution methods, significant purification of benzodiazepine receptor 
subtypes has been achieved (Ransom et al, 1986; Sigel et al, 1983; 
Schoch et al, 1984; Tallman & Gallager, 1979). Using rat cortex, a 
partially purified benzodiazepine receptor preparation was obtained. 
In this preparation a major protein band of 48.5 kD and several 
minor bands (68, 58, 54.5, and 50 kD) were isolated. Analysis of the 
48.5 kD protein in two dimensions shows it to co-localize with the 
photo-labeled alpha subunit. Using this benzodiazepine receptor 
preparation, 6 murine monoclonal cell lines were generated, as tested 
for by solid phase radioimmunoassay. Western blots to receptor 
proteins separated electrophoretically demonstrate the presence of 
two immunoreactive bands of 48.5 and 54.5 kD. These results are 
similar to those observed in bovine brain (Haring et al, 1985). In 
addition, immunoblot studies using one monoclonal antibody, H10, 
suggest a common epitope is shared by both subunits. In an 
attempt to further delineate the molecular structure and to explore 
the possibility that homology between the alpha and beta subunits of 
the GABAa/benzodiazepine receptor exists, these proteins were 
analyzed by methods of limited proteolysis. Results indicate that 
degradation of both 48.5 kD and 54.5 kD proteins yielded several 
limited peptides as determined by molecular weight. Homology of 
these receptors may, thus, exist at the level of primary protein 
structure. 
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Materials & Methods 
Benzodiazepine Receptor Purification 
Purification of the benzodiazepine receptor was carried out by 
affinity chromatographic methods utilizing a benzodiazepine coupled 
agarose resin. Preparation of the ligand affinity column and isolation 
of the benzodiazepine receptor have been discussed in detail 
elsewhere (Ransom et al, 1986; Sigel et al, 1983; Schoch et al, 1984; 
Tallman & Gallager, 1979). Briefly, the flurazepam derivative, R07- 
1986/001, was coupled to an agarose gel support at the carboxy- 
terminus of a positively charged 15-atom spacer arm (succinyl- 
methylimino-bis-propylamino carboxylmethyl agarose carboxamide). 
A volume of 100 ml of the N-hydroxysuccinimide ester of this gel 
(Affi-Gel 15, Bio-Rad) was washed with absolute ethanol and 
suspended in al50 ml volume. The agarose was reacted with 100 
mg of ligand at 4° C overnight. The coupled gel was washed with 1 
liter of distilled water using a sintered glass funnel under light 
vacuum. The agarose gel was resuspended in 25 mM potassium 
phosphate buffer at pH 7.3 and filtered just prior to use. 
Whole rat brain was homogenized inlO volumes of 25 mM 
potassium phosphate buffer containing 0.1 mM 
phenylmethylsulfonylfluoride (PMSF), 2.5 pg/ml trypsin inhibitor, 5 
mM ethylene-diamine-tetraacetic acid (EDTA) and 50 pM 
benzamidine at pH=7.3 (PIB) using a Polytron tissue homogenizer 
(Brinkman Instruments). The homogenate was then centrifuged at 
40,000 x g for 20 minutes and the pelleted membranes homogenized 
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and centrifuged twice more in the same manner. The washed pellets 
were then frozen overnight at -80° C. 
The following morning, pellets were again homogenized and 
centrifuged in the same buffer twice. The membranes were 
suspended in 10 volumes of 1.0% Lubrol PX (Sigma Chemical 
Company) in PIB and stirred at 4° C for 1 hr. The solubilized 
membrane suspension was ultracentrifuged at 105,000 x g for 30 
minutes. Supernatants were pooled and stirred with the R07- 
1986/001 coupled agarose (approx. 3:1, V/V) for 1 hr. at 4 ° C. The 
Affigel was washed and filtered 2 times with 1.0% Lubrol PX and 4 
times with 5 mM 3-(chloramidopropyldimethyl-amino)-l- 
propansulfonate (CHAPS) in comparable volumes. The 
benzodiazepine receptor was eluted from the Affigel overnight 
with 1.0 mM Flurazepam in PIB with CHAPS at 4 ° C. 
The next morning the Affigel was filtered and the filtrate 
dialyzed against 1 liter of PIB with CHAPS using an Amicon filtration 
apparatus (membrane size PM30). Following the dialysis, the 
receptor mixture was then concentrated to a final volume of 2-3 mis 
and stored at - 80 ° C for future use. The benzodiazepine coupled 
Affigel was washed with a generous volume of distilled water and 
stored for reuse in 70% ethanol at 4 0 C. 
The partially purified benzodiazepine receptor preparation was 
further purified by gel exclusion chromatography. Sephadex G-200 
resin (Pharmacia) was preswollen for 48 hours in distilled water, a 
200 ml bed volume poured, and the column eluted with 2 column 
volumes of 5 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic 
acid (HEPES). A 2.0 ml sample of the purified benzodiazepine 
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receptor preparation (as described above) containing 1 mg/ml 
Dextran-2000 Blue was applied to the column and eluted with 5 mM 
HEPES at 4 ° C. Fractions of 1.0 ml were collected and 10 pi samples 
of each fraction analyzed by gel electrophoresis. Samples enriched in 
the benzodiazepine receptor (48.5 kD band) were pooled and 
lyophilized. 
Anti-Benzodiazepine Receptor Antibody Screening bv Solid Phase 
Radioimmunoassay 
Initial screening of polyclonal and monoclonal antibody titers 
was carried out by a previously described solid phase 
radioimmunoassay (Kun et al, 1978). Briefly, 50 pi of receptor 
preparation at a concentration of approximately 1 pg/ml was 
passively absorbed to polyvinyl chloride microtiter wells 
(approximately 0.05 pg receptor protein). Unreacted sites were then 
blocked with a 5% solution of bovine serum albumin (BSA). 
Polyclonal serum or monoclonal supernatant was then incubated in 
wells for 24 hours at 4 ° C. After extensive washing, wells were then 
reacted at room temperature for 2 hours with 125I-goat anti-mouse 
IgG having a specific activity of 500,000 cpm/ml. Following 
extensive washing, wells were then counted in a Beckman Model 
5000 gamma counter. 
Production of Monoclonal Antibodies 
Monoclonal antibodies to the benzodiazepine receptor were 
produced using the methods originally described by Kohler & 
Milstein (1975) with modifications (Kohler, 1980). Female BALB/c 
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mice, ages 18-20 weeks, were injected intraperitoneally with 
purified benzodiazepine receptor preparation according to the 
following schedule: Week 1, 75 pg receptor protein in 0.5 mis 
Freund's complete adjuvant; Week 2, 50 pg receptor protein in 0.5 
mis Freund's incomplete adjuvant; Week 3, 50 pg receptor protein in 
250 pi 25 mM potassium phosphate buffer, pH 7.3. Mice were bled 
retroorbitally and the serum polyclonal antibody titer determined by 
solid phase radioimmunoassay as described above. 
Two days after final injection, mice with the highest polyclonal 
titers were sacrificed and spleens dissected under sterile technique. 
Splenic lymphocytes from a single mouse were suspended in 10 mis 
Hank's Balanced Salt solution (Gibco) and pelletted. One confluent 75 
cm2 tissue culture flask of the non-secreting myeloma cell line, AG6- 
53 (obtained from Dr. E. Hawrot, Yale), was pelleted, washed, and 
recentrifuged in an identical fashion. Cells were then co-suspended 
in 20 mis of Hank's ,pelleted, and the supernatant discarded. Cells 
were resuspended in a minimal volume of Hank's by gentle agitation 
and 1.0 ml of 50% polyethylene glycol (Sigma Chemical Company, 
3000-3700) added dropwise over 1 minute with gentle swirling. In 
a similar fashion, a total volume of 20 mis of high glucose formula 
Dulbecco's Minimum Essential Medium (DMEM) supplemented with 
10% fetal calf serum, 50 pM hypoxanthine, 0.2 pM aminopterin, and 
8 pM thymidine (Sigma Chemical Company) was added. Cell 
suspensions were then aliquoted dropwise in 96 well microtiter 
plates from which hybridoma lines were selected. Clones testing 
positive to receptor preparation by solid phase radioimmunoassay 
were expanded in 75 cm2 tissue culture flasks using high glucose 
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DMEM supplemented with 10% fetal calf serum and 50 jiM 
hypoxanthine and 8 pM thymidine. 
High titer ascitic fluid was produced by passing positive 
hybridoma cell lines into syngeneic mice by intraperitoneal injection. 
Mice were initially primed with intraperitoneal injection of 0.5 ml of 
pristane five days before injection of approximately 4 x 106 cells in 
1.0 ml serum free medium. Ascitic fluid obtained by paracentesis 
was stored at -80 ° C. 
Gel Electrophoresis 
Separation of receptor proteins for molecular weight 
determination, analysis by immunoblot, 2-dimensional 
electrophoretic analysis, and limited proteolytic digestion was 
attained utilizing a discontinuous sodium dodecyl sulfate (SDS) 
polyacrylamide gel system as described by Laemmli (1970). 
Routinely, 7.5% acrylamide separating gels were used for analysis of 
purified benzodiazepine receptor preparations and western blotting, 
whereas 15% gels were required for resolution of peptide fragments 
derived from limited proteolysis. Prior to application on gels, 
samples were boiled for 5 minutes in 0.2 M Tris, pH 6.8, containing 
2-mercaptoethanol, 10% glycerol, 2.3% SDS and 0.001 % bromphenol 
blue. Low molecular weight standards (Dalton VII-L, Sigma) were 
used to determine approximate molecular weights of receptor 
proteins and proteolytic fragments. Gels were stained in a solution of 
0.25% Coomassie brilliant blue, 50% methanol, 10% acetic acid on an 
Eberbach clinical rotator. Subsequent destaining of gels was carried 
out with rotary shaking in a solution of 50% methanol, 10% acetic 
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acid. As needed for preservation or autoradiography, gels were 
dryed on chromatography paper (Whatman 3mmChr) at 80 0 C for 2 
hours under vacuum using a slab gel dryer (Bio-Rad, Model 224). 
For autoradiography, dried gels were placed against Kodak X-omat 
film in an intensifying cassette for 72 hours at -80 ° C. 
Screening of Monoclonal Antibodies bv Western Blotting 
Either washed membrane or purified receptor preparations 
were run on 7.5% polyacrylamide slab gels as described above. 
Separated proteins were then transferred to nitrocellulose paper by 
high-intensity transverse electrophoresis for 2 hours at 1.0 A in a 
buffer containing 25 mM Tris, 192 mM glycine and 20% (V/V) 
methanol (Towbin et al, 1979). Unreacted sites on the nitrocellulose 
paper were blocked by three 10-minute incubations in 10 mM 
phosphate buffered saline, 140 mM NaCl, pH 7.4 with 0.05% Tween 
(PBS/Tween). Primary incubation of ascitic fluid at a dilution of 
1:1000 in PBS/Tween was performed overnight at 4 0 C. The 
nitrocellulose was then washed at room temperature with 
PBS/Tween to eliminate unreacted primary antibody. For the 
secondary incubation 125I-sheep anti-mouse IgG was used at a final 
specific activity of 750,000 cpm/ml for 2 hours. This was succeeded 
by 3 more 10-minute incubations in PBS/Tween. The nitrocellulose 
was then allowed to air dry, placed against Kodak X-omat film and 
loaded in an intensifying cassette for up to 18 hours at -80 ° C. 
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Iodination of the Benzodiazepine Receptor 
Iodination of the purified benzodiazepine receptor preparation 
was carried out by the method described by Bolton and Hunter 
(1973) with the following modifications: 250 pC 125I-Bolton/Hunter 
reagent (125I-BH, New England Nuclear) was gently concentrated to 
dryness using a dessicant-filtered N2 stream (15 min.). 
Approximately 10 pg of lyophilized receptor protein in 25 pi of 100 
mM Na2HP04 , pH 8.0 was then added to the 125I-BH vial and the 
reaction carried out for 30 min. at 0 ° C. Unreacted 125I-BH was 
removed by adding 400 pi of 0.2 M glycine in 100 mM Na2HP04 , pH 
8.0 and allowing the reaction to proceed another 5 minutes. The 
reaction mixture was then chromatographed on a Sephadex G-50 
(fine) column using a solution of 50 mM Na2HP04 , pH 7.4 containing 
0.25 % gelatin, 0.02 % NaN3 , and 0.1 % SDS as eluant. Fractions of 
200 pi were collected. Aliquots (5 pi) of each fraction were counted 
on a Beckman Model 5000 gamma counter. Radioactive fractions 
were then subjected to gel electrophoresis, and autoradiography, as 
described above. Fractions containing 125I-labeled benzodiazepine 
receptor were then aliquoted into 100 pi volumes and stored at - 80 
°C 
Peptide Mapping bv Limited Proteolysis 
Peptide mapping of the benzodiazepine receptor was carried 
out by limited proteolysis as described by Cleveland, et al (1977) 
with the following modifications. This 125I-BZR benzodiazepine 
receptor preparation was first subjected to gel electrophoresis on a 
7.5% polyacrylamide gel as described above. Visualization by 
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coomassie blue staining was enabled by the addition of "cold" carrier 
receptor, as necessary. Protein bands were then cut from the slab 
gel and the gel slices washed with agitation for 30 minutes in 125 
mM Tris-HCl, pH 6.8 containing 0.1% SDS (Tris buffer). Gel pieces 
were then applied to the wells of a long SDS-polyacrylamide gel (4.5 
cm, 3% stacking gel; 11.5 cm, 15% separating gel). Gel slices were 
then overlayed with approximately 50 pi of Tris buffer containing 
20% glycerol (V/V) and a trace of bromphenol blue. Staphylococcus 
aureus V8 protease (Sigma) was diluted in Tris buffer containing 10% 
glycerol (V/V) and a trace of pyronin Y. The desired amount of 
protease solution (0.001 - 0.1 pg) was layered on top and the protein 
subjected again to electrophoresis overnight at 60 V. Gels were dried 
and placed against Kodak X-omat film in an intensifying cassette for 
72 hours at -80 ° C. 
Two Dimensional Gel Electrophoresis 
This method makes use of the substitution of a nonionic 
detergent for SDS, thus allowing isoelectric focusing in the first 
dimension before size separation in the second. Samples (20 pi) of 
125I-labeled benzodiazepine receptor were brought to a final volumn 
of 80 pi with a solution containing 9.0 M urea, 4% NP-40 (nonidet P- 
40, Sigma), 2% ampholines pH 3-10 (Biorad), and 5% 6- 
mercaptoethanol. The samples were then subjected to 2D 
electrophoresis according to the procedure described by O'Farrell 
(1975), and modified by Ames & Nikiado (1976); 7.5% acrylamide 
gels were used for the second dimension as described above. 
4?1 
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Results 
Receptor Purification & SDS-PAGE Analysis 
Benzodiazepine receptor was initially purified from rat cortical 
membranes by affinity chromatography. Results of SDS 
electrophoretic analysis of this partially purified benzodiazepine 
receptor preparation are seen in Figure 1. Several protein bands 
ranging in molecular weight from 45 to 68 kD are visualized by 
coomassie blue staining. Of these, 48.5 kD and 68 kD bands 
represent the major protein constituents. In addition to these bands, 
proteins of molecular weights 50 kD, 54.5 kD, and 58 kD copurify by 
affinity chromatography. A fifth minor protein band weighing 45 kD 
represents the major phosphoprotein in this preparation and has 
been implicated to be the enzyme pyruvate dehydrogenase (Gallager, 
Sweetnam, and Tallman, in preparation). In addition, there exist 
other minor bands of higher (70-90 kd) and lower (<35 kD) 
molecular weights. 
Gel filtration chromatography (G-200) of the partially purified 
benzodiazepine receptor preparation resulted in fractions of varying 
protein composition as evidenced by SDS gel electrophoresis (Figure 
2). Fractions enhanced in the major protein bands (48.5 kD, 54.5 kD, 
58 kD, and 67 kD) eluted early with the Blue Dextran front and were 
pooled for iodination and subsequent proteolytic analysis. 
Interestingly, the 50 kD protein eluted later and was pooled 
separately. Figure 3 illustrates the relative purification of the 
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receptor preparation with elimination of the 50 kD and lower 
molecular weight proteins. 
Monoclonal Antibodies & Immunoblot Analysis 
Balb-C mice were successfully immunized using the 
benzodiazepine receptor preparation as indicated by solid phase RIA 
(Figure 4). Three animals with the highest polyclonal titers were 
sacrificed for splenic lymphocytes and cell lines established as 
described in Materials & Methods. Following 7-10 days in culture, 
solid phase RIA demonstrated antibody positive cell lines with 
counts of 800-1500, whereas supernatants from lines not producing 
anti-benzodiazepine receptor yielded background values of 400-500. 
Positive lines were retested and then expanded in tissue culture 
flasks. In total, 6 cell lines secreting anti-benzodiazepine receptor 
antibodies were passed into mice and high titer ascitic fluid 
prepared. Figure 5 shows the solid phase RIA data of diluted ascites 
against a limited receptor concentration (upper limit of assay 
approximately 1500 cpm). Ascitic fluid tested positive in all cases 
and at dilutions of 1:10,000 in the case of some cell lines (e.g. E9, D5, 
and B2). 
Following initial screening by solid phase RIA, specificity of 
antibodies was determined by Western blot analysis. Immunoblots 
of ascitic fluid demonstrated two distinct binding patterns, as 
characterized by the cell lines E9 and H10. As seen in Figure 6, E9 
primarily labels a protein of molecular weight 48 kD - 50 kD. Ascites 
from cell line H10, in addition to labeling the protein band at 48 kD - 
50 kD, demonstrated recognition of a band of 55 kD. Both antibodies 
■ 
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appeared to demonstrate minor labeling of a protein of molecular 
weight 45 kD. Monoclonal antibodies from cell lines B2 and D5 shared 
binding patterns similar to E9, whereas A2 duplicated immunoblots 
seen with H10. Western blot analysis in the ensuing data is 
comprised of the two representative cell lines E9 and H10. 
Iodination of the BZR 
Purified benzodiazepine receptor obtained by affinity and gel 
exclusion chromatography methods served as substrate for 
iodination. Following conjugation of 125I-Bolton/Hunter (125I-BH) 
reagent to 10 pg of the reconstituted receptor lyophilizate, the 
iodination mixture was subjected to Sephadex G-50 chromatography 
with the elution of 2 major radioactive peaks (figure 7). Analysis of 
the fractions by SDS acrylamide electrophoresis and autoradiography 
(Figure 8) demonstrated the first of these to represent the 125I-BH- 
labeled receptor preparation (125I-BZR). Electrophoresis and 
autoradiography of fractions comprising the second, larger 
radioactive peak failed to demonstrate any protein bands. It is most 
likely that this peak represents 125I-BH-conjugated glycine. 
Radioactivity incorporated into the benzodiazepine receptor fraction 
represented less than 5% of the starting 250 pCi total. 
Limited Proteolytic Map of the 125I-BZR 
Iodination of the receptor preparation yielded 4 major 
radioactive bands in the region of the suggested receptor subunits. 
These corresponded to the 48.5kD, 54.5 kD, 58 kD and the 68 kD 
bands. These bands were subjected to limited proteolytic 
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degradation using increasing concentrations of Staph, aureus V8 
protease (SAP). A sufficient concentration range of protease was 
employed to digest major bands completely into (SAP) limiting 
peptide fragments. Conditions employed, nevertheless, utilized small 
amounts of SAP, as all bands seemed sensitive to the protease 
(optimum range of 0.001 - 0.03 jig). Proteolytic fingerprints 
generated for each of the major bands are illustrated in Figures 9 
and 10. 
Once the conditions for limited proteolysis were optimized, a 
second digest experiment was conducted in an attempt to compare 
proteolytic fingerprints. In this experiment, each of the individual 
protein bands were run in adjacent lanes and subjected to enzymatic 
degradation with an identical amount SAP (0.001 and 0.01 jllg). 
Comparison of neighboring proteolytic fingerprints was thus 
facilitated (Figure 11). 
2-Dimensional Gel Analysis 
The iodinated benzodiazepine receptor preparation was 
subjected to two dimensional electrophoresis as demonstrated in 
Figure 12. The experiments were performed in quadruplicate, in the 
presence and absence of molecular weight/isoelectric standards. In 
addition, 125I-labeled benzodiazepine receptor preparation was run 
separately in the second dimension for reference. Results indicated 
that the four major protein bands (48.5 kD, 54.5 kD, 58 kD, and 67 
kD) focused within the experimental pH range of 7.0 - 4.5. 
Isoelectric focussing revealed the 54.5 kD and 58 kD bands to be 
comprised of more than one protein constituent The two 58 kD 
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constituents demonstrated nearly identical pi's to those of two 54.5 
kD proteins (approximately 6.0). In addition, isoelectric focussing of 
the 54.5 kD band reveal it to be comprised of a larger, slightly more 
basic protein having an apparent pi of 6.5 - 7.0. 67 kD and 48.5 kD 
bands were slightly more acidic, with pi's of 4.7 and 4.8, 
respectively. Apparent molecular weights and isoelectric points of 
all bands were unchanged by the presence of the protein standards. 
Electrophoretic analysis in two dimensions enabled comparison 
of the iodinated benzodiazepine receptor preparation to receptor 
preparation subjected to coomassie blue staining and E9 
immunoblotting, as well as to rat cortical membranes subjected to 
photolabeling with 3H-Flunitrazepam (Figures 13 & 14). The 
apparent molecular weight and isoelectric point of the 48.5 kD band 
were similar to those of the immunoreactive and photolabeled 
protein. These were in agreement as well with the coomassie blue 
stained major protein. 
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Discussion 
In recent years, extensive investigation into the GABAa 
receptor has lead to a fuller understanding of its molecular structure 
and function. It has become increasingly clear that GABA-ergic 
transmission occurs when GABA binds to a post-synaptic receptor, 
resulting in increased chloride flux through an associated protein 
channel. The 1,4- benzodiazepines bind directly to this complex, 
increase the likelyhood of channel opening in response to GABA 
binding (Choi et al, 1981), and thus, serve to enhance GABA-ergic 
activity. Binding has been shown to be rapid, reversible, and 
saturable, as well as to be influenced by the presence of GABA. The 
complex has thus been referred to as the GABAa/benzodiazepine 
receptor. A variety of molecular approaches, including affinity 
purification, electrophoretic analysis, and photo-labeling experiments 
have been used in an attempt to elucidate the proteins associated 
with this complex. Such approaches have revealed two different 
benzodiazepine binding proteins associated with the GABAa receptor 
having molecular weights of 50 and 55 kD, respectively. Further 
studies using antibodies specific for these proteins have lead to their 
respective description as the alpha and beta subunits of the 
GABAa/benzodiazepine receptor complex. The relationship between 
these proteins remains to be clarified. 
In this paper, aspects of the molecular structure, including the 
putative heterogeneity of the benzodiazepine receptor were studied. 
Various methods of investigation in addition to those above were 
employed, including proteolytic mapping, and molecular studies 
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using monoclonal antibodies. Experimental results using these 
combined modalities suggest, rather, that some structural similarity 
among receptor subunits may exist. 
Initial detergent extraction with Lubrol PX has been previously 
shown to differentially solubilize the "central" or clonazapam 
specific/GABA-enhanced benzodiazepine binding site from a 
"peripheral" receptor (defined by high affinity binding of the 
benzodiazepine analog R05-4864 ) (Yosufi et al, 1979). This partial 
purification results in an 800-1000 fold increase in benzodiazepine 
binding activity over crude homogenates. This activity is 
characterized by high-affinity (<10 nM) binding sites for both 
benzodiazepine agonists (3H-Flunitrazepam) and antagonists (R015- 
1788), as well as both high and low affinity sites for GABA. In 
addition to co-purification of the benzodiazepine and GABA sites, 
enhancement of benzodiazepine binding by GABA in such 
preparations has been demonstrated as well, indicating preservation 
of allosteric properties of the complex. 
Analysis of this partially purified benzodiazepine receptor 
preparation by SDS gel electrophoresis and coomassie blue staining 
reveals the presence of multiple protein bands (48.5 kD, 50 kD, 54.5 
kD, 58 kD, and 68 kD). The major band in this preparation, 48.5 kD, 
has been shown to co-migrate on polyacrylamide gels with the major 
photo-labeled species (data not shown), and is thought to represent 
the alpha subunit of the GABAa receptor. This was confirmed by 
analysis of the receptor preparation using 2-dimensional 
electrophoresis. This technique enables resolution of proteins based 
not only on molecular weight, but also on the basis of the protein's 
. 
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isoelectric point (pi). Autoradiography of the 125I-labeled 
benzodiazepine receptor preparation demonstrated a spot with an 
apparent molecular weight of 48.5 kD and a pi of approximately 4.8. 
This coincided with findings demonstrating co-localization in 2- 
dimensions of both the coomassie blue stained protein and the 
photo-labeled receptor (Mr=48.5 kD, pi approximately 4.8). Barnard 
(1984) has previously reported the pi of the GABA/benzodiazepine 
receptor complex as 5.6, though isoeletric focusing of individual 
subunits has yet to be reported. In the literature, there remains a 
variety of apparent molecular weights described as representing the 
major photo-labeled moiety ranging from 48.5 - 53 kD (Sigel et al, 
1983; Kuriyama et al, 1984; Sigel & Barnard, 1984; Mohler et al, 
1984; Fischer & Olsen, 1986). Part of this variability may be 
explained by the different species studied (e.g. rat, bovine), or may 
represent differences in electrophoretic techniques, including the 
composition of gels (percentage of acrylamide) and electrophoresis 
time. Two other bands of apparent molecular weight 55 kD and 47 
kD incorporate relatively minor amounts (<5%) of 3H-flunitrazepam 
under optimal conditions for photo-activation (Sweetnam, Nestler, & 
Tallman, in preparation). These were detectable only by gel slice 
techniques and were not visualized by fluorography. Sieghart & 
Karobath (1980) have reported receptor heterogeneity for the 
benzodiazepines by covalent labeling of bands with apparent 
molecular weights of 50 kD, 53 kD, 55 kD, and 59 kD using the photo- 
activated nitrogen containing benzodiazepine, 3H-flunitrazepam. No 
attempt to inhibit proteolysis was made in these experiments, and 
endogenous proteases shown to be present in membrane fractions 
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(Klotz et al, 1984) might account for this observed heterogeneity. 
Several protease inhibitors (benzamidine, soybean trypsin inhibitor, 
and PMSF) are employed in our purification protocol. For this reason 
it is unlikely that endogenous proteolytic activity contributes to our 
photo-labeling results. We routinely label only one major protein 
band in our preparation corresponding to the alpha subunit. 
Monoclonal antibodies to the rat benzodiazepine receptor were 
raised in mice using the partially purified receptor preparation. 
Techniques using secondary antibody recognition suggest these 
antibodies to be of the IgM subclass (Sweetnam, personal 
communication). This would be consistent with the rapid 
immunization and harvesting schedule utilized in our protocol. As 
demonstrated by immunoblotting techniques to both purified 
receptor and whole brain homogenates, our monoclonal antibodies 
demonstrate specificity for the major receptor band of 48.5 kD (50 k 
band or alpha subunit). 2-Dimensional electrophoretic analysis has 
confirmed the specificity of monoclonal line Eg for the alpha subunit. 
Western blots to 2-D gels using E9 show recognition of a protein with 
apparent molecular weight of 48.5 kD and an isoelectric point of 
around 4.8 (as described above). 
Several of the monoclonals, as typified by H10, recognize a 
second higher molecular weight species of approximately 55 kD on 1- 
dimensional gels. Subsequent subcloning of these cell lines has 
confirmed that a single antibody is responsible for the recognition of 
both bands. The molecular basis for this dual recognition remains at 
the present uncertain. Gallombardo (in press) has shown H10 (and 
E9) capable of increasing the affinity of the membrane bound 
■ 
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receptor for 3H-Flunitrazepam, 3H-R015-1788 and 3H- muscimol. In 
light of these binding studies to membrane bound receptor, 
immunoblot data suggests a common cell surface determinant on 
both 48.5 kd and 55 k bands. However, the molecular basis for this 
shared epitope cannot be inferred from immunoblot data alone. 
With the recent generation of monoclonal antibodies to the 
bovine benzodiazepine receptor, Mohler and colleagues have utilized 
similar techniques to explore the molecular structure of the 
benzodiazepine receptor (Haring et al, 1985). Results in the rat are 
identical to those obtained using the bovine benzodiazepine receptor. 
Immunoblot analysis revealed the existence of immunoreactive 
proteins of 50 and 55 kD in all brain regions examined. 
As stated above, the existence of multiple, heterogeneous 
"central-type" benzodiazepine receptors has been postulated. This 
hypothesis was initially based on the pharmacology of the 
triazolopyridazine, CL218,872, in different brain regions (Squires et 
al, 1979; Klepner et al, 1979). Autoradiographic studies at the light 
microscopic level seemed to corroborate this finding (Young & Kuhar, 
1980; Young et al, 1981). This agreement was not absolute, however, 
as CL218,872 binding in cerebellum suggested a single receptor 
subtype, whereas autoradiography demonstrated receptor 
heterogeneity (Niehoff et al, 1982). Several laboratories have 
reported the photolabeling of benzodiazepine receptor subtypes in 
the hippocampus and striatum (BZi and BZ2), whereas photo-labeling 
in cerebellum revealed only a single receptor subtype (BZX). 
Although such regional heterogeneity might offer a tenable 
explanation for the two major receptor subtypes seen, recent 
■ 
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evidence suggests that these subtypes may in fact be subunits of a 
single receptor species. Photo-labeling studies using the GABA 
agonist [3H]muscimol demonstrate labeling of the beta subunit in 
bovine brain (Casalotti et al, 1986). Monoclonal antibodies to the 
bovine benzodiazepine receptor demonstrate the 55 kD protein in all 
brain regions studied, including the cerebellum (Haring et al, 1985). 
Furthermore, by immunoprecipitation with either of two monoclonal 
antibodies recognizing the different "receptor proteins", this group 
was able to demonstrate co-precipitation of the entire population of 
binding sites (benzodiazepine, as well as low and high affinity GABA) 
found in their purified preparations. These results were interpreted 
to suggest the existence of a homogenous population of 
GABAa/benzodiazepine receptors comprised of two different receptor 
protein subunits (alpha and beta). Thus, multiple subunits of a large 
macromolecular complex, rather than receptor heterogeneity may 
account for the 50 and 55 kD bands. 
As noted above, allosteric properties of the receptor complex 
remain intact in our partially purified preparation, implicating 
conformational integrity of the GABA/benzodiazepine receptor 
complex. With this in mind, attempts to further purify the receptor 
complex on the basis of its macromolecular size were pursued. Gel 
exclusion chromatography on Sephadex G-200 enabled enhancement 
of the major bands (48.5 kD, 54.5 kD). Many bands of higher and 
lower molecular weights, as well as the 50 kD band, eluted later from 
the column. The early elution of the major bands with the blue 
dextran marker (Mr= 2000 kD) is consistent with the possibility of 
their association as a large macromolecular complex. Utilizing a 
■ 
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variety of approaches, investigators have implicated the 
GABA/benzodiazepine receptor complex to have an apparent 
molecular weight of 200 - 900 kD (as review by Fischer & Olsen, 
1986). In particular, by methods of gel filtration chromatography, 
the native receptor has been estimated to have a molecular weight of 
220 kD (Yosufi et al, 1979; Chang & Barnard, 1982; Martini et al, 
1982; Fischer & Olsen, 1986). Thus, the exclusion size of the 
Sephadex G-200 would be expected to result in elution of the 
receptor complex with the void volume as seen with the 48.5 and 
54.5 kD bands. 
With the knowledge that the 48.5 kD and 54.5 kD proteins 
(alpha and beta subunits) shared a common immunoreactive epitope, 
it remained interesting to speculate about potential homology 
between these two proteins. Though much work in the field has 
focused on the apparent heterogeneity or multiplicity of 
benzodiazepine receptor proteins, few studies have sought to explore 
at a molecular level their relatedness. The question of homology was 
approached using methods of limited proteolytic degradation. In 
order to adequately visualize peptide fragments, the receptor was 
first iodinated and results determined by autoradiography. By 
subjecting the major protein bands in our highly purified receptor 
preparation to SAP digestion, it was possible to generate a proteolytic 
map or "fingerprint" of the receptor. 
Results show that all of the major bands were susceptible to 
degradation by the V8 protease within the same concentration range 
(0.001 - 0.03 jig). The peptide fragments visualized by 
autoradiography may not represent the "complete" peptide map of 
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these proteins due to variable incorporation of the 125I-BH based on 
amino acid composition. Nevertheless, limiting peptides 
characteristic of individual bands were generated. Most striking 
among these were those of the 48.5 and 54.5 kD bands. Although 
variations in their limited peptide maps exist, both proteins 
demonstrate 2 major limiting peptides of apparent molecular weights 
21 and 23 kD. This reproducible peptide pattern may represent 
some degree of homology at the level of primary protein structure. 
Interpretation of this data was supplemented by 
electrophoresis of the iodinated preparation in two dimensions. 
Isoelectric focusing of the 48.5 band demonstrated its homogeneity 
with a pi in the acidic range (approximately 4.8 ). The 54.5 band, 
however, appeared to be comprised of several distinct protein foci. 
The peptide map of this band, therefore, may represent the 
combined pattern of several, potentially unrelated proteins. 
Interestingly, both the 54.5 and 58 kD bands seem to share the 
protein spots with pi's of approximately 6.0. Whether these protein 
foci represent distinctly different proteins with differing primary 
structure is uncertain. Alternatively, their similar pi's might be 
explained by slight differences in carbohydrate content of an 
otherwise identical protein molecule. Cleavage of a small, neutral 
peptide, be it physiological or artifactual, might account for the 
molecular weight differences. In the peptide maps of the 54.5 and 
58 kD bands, faint bands of identical molecular weight can be seen. 
Based on similar pi values and apparently shared proteolytic 
fragments, it remains interesting to speculate that these various foci 
represent the same primary protein. In addition to these proteins, 
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the 54.5 kD band is comprised of a larger, more basic (pi-6.5-7.0) 
protein. The more diffuse focusing of this protein may represent an 
artifact of the gradient at the more basic spectrum, or might again be 
explained by variable glycosylation of the same protein. Both 58 and 
68 kD proteins demonstrated unique peptide maps, distinct from 
either of the two lower molecular weight bands. The shared limiting 
peptides of the 48.5 and 54.5 kD bands may thus be the result of 
homology between the more basic 54.5 kD protein (pl=6.5-7.0) and 
the 48.5 kD band. Immunoblot studies to two dimensional gels with 
the monoclonal antibody H10 may serve to clarify this relationship. 
In tryptic digest experiments done by Eichinger & Sieghart 
(1985), they demonstrated differential degradation of 3H- 
Flunitrazepam-labeled 51 and 55 kD proteins. They cite this 
differential degradation pattern as supportive evidence of different 
receptor subtypes. Analysis of their data shows that although tryptic 
degradation results in different major limiting peptides, tryptic 
digestion of the 51 kD protein generates minor bands of 42 and 45 
kD. These appear identical to the major [3H]Flunitrazepam-labeled 
limiting peptide fragments (42 and 45 kD) characteristic of the 55 kD 
band. Thus, though interpreted to implicate receptor heterogeneity, 
an argument for structural homology between the same two proteins 
can be made. Because the fragments generated in their experiments 
represent photo-labeled peptides, such results would implicate 
homology at the benzodiazepine binding portion of the receptor. At 
present, it is not possible from our data to ascribe homology to a 
given receptor domain. Proteolytic experiments utilizing photo- 
labeled receptor remain to be done. In addition, immunoblot 
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experiments using our monoclonal antibodies against these 
proteolytic maps may enable identification of peptide epitopes, 
either that specific for the 48.5 or that shared by both the 48.5 and 
55 kD proteins. Until the various receptor bands are cloned and their 
sequences defined, such lines of investigation may help to elucidate 
the relatedness of these various proteins and their relationship to the 
GABAa /benzodiazepine receptor. 
In addition to the 48.5 and 54.5 kD proteins discussed above, 
several other proteins are observed in our partially purified receptor 
preparation (50 kD, 58 kD and 68 kD). The identity of these bands is 
uncertain, although they remain unrecognized by our monoclonal 
antibodies, and the two larger proteins demonstrate unique peptide 
maps different from either the 48.5 or the 54.5 kD bands. Although 
these protein bands may be regarded as contaminants, other possible 
explanations for their co-purification exist. Several proteins may in 
fact co-purify by our affinity chromatography methods based on 
their ability to bind benzodiazepines. Even proteins with low 
affinities for the benzodiazepines, if present in large amounts in 
tissue, might be expected to represent a significant constituent of the 
partially purified preparation. Albumin, for example, is known to 
bind numerous drugs, including the benzodiazepines (Fehske et al, 
1979). In addition, other "peripheral" receptors for the 
benzodiazepines have described, including a low affinity (pM) Ca2+- 
Calmodulin kinase associated receptor (Bowling & DeLorenzo, 1982). 
A second, and as yet unexplored possibility, is that various 
bands in our preparation represent different stages in the post- 
translational modification of the receptor. It has been demonstrated 
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that the receptor is a glycoprotein (Gavish & Snyder, 1981; 
Stephenson & Olsen, 1983; Sweetnam & Tallman, 1986). 
Glycosylated versus non-glycosylated, as well as "pre-" and "pre/pro- 
" forms of the receptor might account for observed "heterogeneity". 
In addition, multiple allelic variants of the benzodiazepine receptor 
within the genome may exist. Such genetic variation in enzymes 
("isozymes") is a well documented phenomenon in both physiologic 
and pathophysiologic states in the human. Though no example of 
such an "iso-receptor" has been demonstrated to date, allelic variants 
of the benzodiazepine receptor would have significant implications 
for many neurologic and psychiatric disorders. 
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Legends to Figures 
Figure 1. Partially purified benzodiazepine receptor preparation 
(Bzr) was run under standard 7.5% SDS-PAGE conditions and 
visualized by coomassie blue staining as described in "Materials & 
Methods." A major protein band of 48.5 kD is seen, as well as other 
minor bands (50, 54.5, 58, and 68 kD). A reference lane of low 
molecular weight standards (Std) is shown, as well. 
Figure 2. The partially purified benzodiazepine receptor 
preparation was subjected to gel exclusion chromatography as 
described in "Materials & Methods." Fractions were collected 
beginning with elution of the Dextran Blue front and were then 
subjected to standard 7.5% SDS-PAGE analysis. As seen here, 
fractions 1-8 elute with the Dextran Blue and are enhanced in the 
48.5, 54.5, 58, and 68 kD bands. These fractions were pooled as 
Sample 1. The 50 kD band elutes later (fractions 9-20) and was 
pooled separately as Sample 2. Reference lanes containing low 
molecular weight standards (Std) and partially purified 
benzodiazepine receptor preparation (Bzr) are also shown. 
Figure 3. Benzodiazepine receptor fractions collected following gel 
exclusion chromatography of the partially purified preparation were 
pooled as shown in Figure 2. The pooled fractions, Samples 1 and 2, 
were then subjected to standard 7.5% SDS-PAGE and coomassie blue 
staining as described in "Materials & Methods." Sample 1 shows 
relative enhancement of the 48.5, 54.5, 58, and 68 kD bands and was 
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saved for iodination and subsequent limited proteolysis. Sample 2 is 
contains the 50 kD, as well as other higher and lower molecular 
weight bands separated by gel exclusion purification. Reference 
lanes containing low molecular weight standards (Std) and partially 
purified benzodiazepine receptor preparation (Bzr) are also shown. 
Figure 4. Balb-C mice were immunized using the partially purified 
benzodiazepine receptor preparation. Sera obtained from each mouse 
before, following primary, and following secondary immunizations 
was subjected to solid phase radioimmunoassay as outlined in 
"Materials & Methods." As shown here, immunization resulted in 
increasing titers of polyclonal sera following each step. Mice with the 
highest polyclonal titers were then identified for generation of 
hybridoma cell lines. 
Figure 5. High titer ascites from 6 murine monoclonal cell lines was 
tested by solid phase radioimmunoassay as described in "Materials & 
Methods." Results here show significant activity at dilutions of 
1:1000 to 1:10,000. Monoclonals E9 and H10 demonstrate 
considerable activity at higher dilutions (1:10,000) and were used for 
subsequent immunoblot experiments. 
Figure 6. Partially purified benzodiazepine receptor preparation 
was subjected to SDS-PAGE and subsequent transverse 
electrophoresis onto nitrocellulose as described in "Material & 
Methods." Immunoblots to the nitrocellulose fixed receptor using E9, 
H10, and control ascites at dilutions of 1:1000 are shown. Low 
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molecular weight standards (Std) and receptor preparation (Bzr) 
subjected to SDS-PAGE and coomassie blue staining are included for 
reference. Two immunoreactive proteins with apparent molecular 
weights of 48.5 and 54.5 kD can be seen. Antibody produced by the 
monoclonal cell line E9 is specific for the 48.5 kD or alpha subunit. 
H10j however, demonstrates cross-reactivity between both the 48.5 
(alpha) and 54.5 kD (beta subunit) bands. Subsequent subcloning 
has shown a single antibody to be responsible for this dual 
recognition. 
Figure 7. Purified benzodiazepine receptor obtained by affinity and 
gel exclusion chromatography methods was subjected to iodination as 
described in "Materials & Methods." The profile of radioactivity 
eluted from the Sephadex G-50 column is shown here. Two 
radioactive peaks can be seen to elute from the column. The minor 
peak appearing with the void volume represents the iodinated 
receptor (125I-BZR) as demonstrated in Figure 8. The second, major 
peak most likely represents Bolton/Hunter reagent coupled to 
glycine. 
Figure 8. Following elution of the iodinated benzodiazepine 
receptor from the Sephadex G-50 column, individual fractions were 
sampled (5pl) and analyzed by 7.5% SDS-PAGE and autoradiography 
as described in "Materials & Methods." The autoradiogram 
demonstrates the iodinated receptor (125I-BZR) in fractions 2-5, the 
first peak seen in Figure 2. 
■ 
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Figure 9. The iodinated benzodiazepine receptor was run under 
7.5% SDS-PAGE conditions, 58 kD and 54.5 kD bands cut from the gel, 
and the gel slices subjected to limited proteolysis on 15% SDS-PAG's 
as described in "Materials & Methods." The autoradiogram pictures 
the individual bands in the absence of staph, aureus V8 protease 
(SAP) in lanes 1. Lanes 2-5 demonstrate increasing degradation of 
the original protein bands into limiting peptide fragments in the 
presence of 0.001, .003, 0.01, and 0.03 jig of SAP, respectively. The 
iodinated receptor is included for reference. In addition, arrows 
indicate appropriate positions of the low molecular weight standards. 
Figure 10. The iodinated benzodiazepine receptor was run under 
7.5% SDS-PAGE conditions, 68 kD and 48.5 kD bands cut from the gel, 
and the gel slices subjected to limited proteolysis on 15% SDS-PAG's 
as described in "Materials & Methods." The autoradiogram pictures 
the individual bands in the absence of staph, aureus V8 protease 
(SAP) in lanes 1. Lanes 2-5 demonstrate increasing degradation of 
the original protein bands into limiting peptide fragments in the 
presence of 0.001, .003, 0.01, and 0.03 pg of SAP, respectively. The 
iodinated receptor is included for reference. In addition, arrows 
indicate appropriate positions of the low molecular weight standards. 
Figure 11. Limited proteolysis of the 68, 58, 54.5, and 48.5 kD 
bands was conducted in parallel using identical SAP conditions as 
described in "Materials & Methods." As seen from left to right, the 
68, 58, 54.5, and 48.5 kD bands were run in the absence (1), with 
0.001 pg (2), and with 0.01 pg (3) of SAP. Comparison of the 
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neighboring peptide maps demonstrate the presence of two shared 
limiting peptides (21 and 23 kD) by the 48.5 and 54.5 kD bands. A 
sharply focussed U-shaped band positioned between the 21 and 23 
kD peptide fragments of the 54.5 kD band represents artifact (see 
figure 9 for comparison). 
Figure 12. Utilizing 2D gel analysis as described in "Materials & 
Methods" the iodinated benzodiazepine receptor preparation was 
examined. The major 48.5 kD protein appears homogeneous in 
composition and has a pi value of approximately 4.8. The 68 kD 
band appears as a single spot at around pH 4.7. Both the 54.5 and 58 
kD bands can be seen to resolve into multiple spots with different 
pi's. Several of these with pi's of approximately 6.0 appear to be 
duplicated in both 54.5 and 58 kD bands. In addition, the 54.5 kD 
band is composed of a more basic protein spot having a pi of 6.5-7.0. 
Figures 13 & 14. In parallel experiments, whole photo-labeled 
membranes were subjected to 2D electrophoresis on three sister gels 
as described in "Materials & Methods." The first was stained for total 
protein by coomassie blue (A): this revealed proteins to be generally 
acidic (pi's 4.5-7.0). The second gel was subjected to 
autoradiography (B) and the third was immunoblotted with E9 
ascites. These gels reveal a single major protein spot with pi's 
identical to the 48.5 kD protein of the iodinated receptor preparation 
(Figure 12) and the partially purified receptor preparation as 
visualized by coomassie blue staining (D). 
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Figure 2 
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Figure 3 
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Figure 5 
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Figure 9 
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Figure 10 
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Figure 11 
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